Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) Gross Margin (2016 - 2025)

Haemonetics (HAE) has 17 years of Gross Margin data on record, last reported at 59.71% in Q4 2025.

  • For Q4 2025, Gross Margin rose 418.0% year-over-year to 59.71%; the TTM value through Dec 2025 reached 59.35%, up 607.0%, while the annual FY2025 figure was 55.04%, 221.0% up from the prior year.
  • Gross Margin reached 59.71% in Q4 2025 per HAE's latest filing, roughly flat from 59.5% in the prior quarter.
  • Across five years, Gross Margin topped out at 59.82% in Q2 2025 and bottomed at 36.35% in Q2 2021.
  • Average Gross Margin over 5 years is 53.05%, with a median of 53.21% recorded in 2022.
  • Peak YoY movement for Gross Margin: tumbled -1126bps in 2021, then skyrocketed 1508bps in 2022.
  • A 5-year view of Gross Margin shows it stood at 51.08% in 2021, then rose by 2bps to 51.98% in 2022, then rose by 2bps to 52.9% in 2023, then grew by 5bps to 55.53% in 2024, then grew by 8bps to 59.71% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 59.71% in Q4 2025, 59.5% in Q3 2025, and 59.82% in Q2 2025.